rF1-V亚单位疫苗联合CD137激动剂诱导的强Th1免疫未提高抗肺鼠疫保护
鼠疫耶尔森菌是鼠疫病原体,也是潜在生物武器,目前尚无FDA批准的疫苗。rF1-V亚单位疫苗加氢氧化铝佐剂是领先候选疫苗,主要诱导Th2体液免疫和较弱的Th1细胞免疫。本研究将CD137通路激动剂SA-4-1BBL加入rF1-V疫苗配方,评估其对肺鼠疫的保护效果,发现强Th1和体液免疫并未转化为保护力的提升,且观察到氢氧化铝佐剂rF1-V疫苗保护效果存在性别偏倚。
要点
- 氢氧化铝佐剂rF1-V疫苗对肺鼠疫的保护效果存在性别偏倚,雌性小鼠保护优于雄性。
- rF1-V联合SA-4-1BBL可诱导强Th1细胞和体液免疫,但未提高保护。
- 初免用rF1-V+氢氧化铝、加强用rF1-V+SA-4-1BBL可在雄性小鼠中提供保护。
核心结论
- rF1-V疫苗联合SA-4-1BBL诱导的强Th1细胞和体液免疫并未转化为对肺鼠疫的增强保护。
- 氢氧化铝佐剂rF1-V疫苗的保护效果存在性别偏倚,雌性小鼠保护优于雄性。
- 初免-加强方案中佐剂组合影响保护效果,双佐剂初免和加强反而失去保护。
研究设计与样本
- 研究使用rF1-V亚单位疫苗,分别联合氢氧化铝佐剂或SA-4-1BBL(CD137通路激动剂),评估对肺鼠疫的保护效果。
- 研究比较了雌性和雄性小鼠的保护效果,并检测了rF1-V特异性抗体滴度和Th1细胞反应。
主要发现
- 氢氧化铝佐剂rF1-V疫苗对肺鼠疫的保护存在性别偏倚,雌性小鼠保护优于雄性,且两性抗体滴度和Th1细胞反应相当。
- rF1-V联合SA-4-1BBL产生了强Th1细胞和体液免疫反应。
- 初免用rF1-V+氢氧化铝、加强用rF1-V+SA-4-1BBL可在雄性小鼠中提供抗肺鼠疫保护。
- 初免和加强均用rF1-V联合两种佐剂虽产生高水平体液和Th1细胞反应,但失去保护。
临床怎么用
- rF1-V疫苗配方中加入SA-4-1BBL虽增强Th1免疫,但未提高肺鼠疫保护,提示不能仅以免疫原性预测保护效果。
- 氢氧化铝佐剂rF1-V疫苗保护效果存在性别差异,疫苗评估需考虑性别因素。
- 初免-加强方案中佐剂组合需优化,双佐剂初免和加强可能损害保护。
局限性
- 研究仅在小鼠模型中进行,结果外推到人类需谨慎。
- 保护机制差异尚未阐明,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yersinia pestis is the causative agent of plague and is a re-emerging pathogen that also has the potential as a biological weapon, necessitating the development of a preventive vaccine. Despite intense efforts for the last several decades, there is currently not a vaccine approved by the FDA. The rF1-V vaccine adjuvanted with Alhydrogel is a lead candidate subunit vaccine for plague and generates a strong Th2-mediate humoral response with a modest Th1 cellular response. As immune protection against Y. pestis requires both humoral and Th1 cellular responses, modifying the rF1-V subunit vaccine formulation to include a robust inducer of Th1 responses may improve efficacy. Thus, we reformulated the subunit vaccine to include SA-4-1BBL, an agonist of the CD137 costimulatory pathway and a potent inducer of Th1 response, and assessed its protective efficacy against pneumonic plague. We herein show for the first time a sex bias in the prophylactic efficacy of the Alhydrogel adjuvanted rF1-V vaccine, with female mice showing better protection against pneumonic plague than male. The sex bias for protection was irrespective of the generation of comparable levels of rF1-V-specific antibody titers and Th1 cellular responses in both sexes. The subunit vaccine reformulated with SA-4-1BBL generated robust Th1 cellular and humoral responses. A prime-boost vaccination scheme involving prime with rF1-V + Alhydrogel and boost with the rF1-V + SA-4-1BBL provided protection in male mice against pneumonic plague. In marked contrast, prime and boost with rF1-V reformulated with both adjuvants resulted in the loss of protection against pneumonic plague, despite generating high levels of humoral and Th1 cellular responses. While unexpected, these findings demonstrate the complexity of immune mechanisms required for protection. Elucidating mechanisms responsible for these differences in protection will help to guide the development of better prophylactic subunit vaccines effective against pneumonic plague.
引用
- Bowen W, Batra L, Pulsifer AR, et al. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Vaccine. 2019. PMID: 31416643. doi:10.1016/j.vaccine.2019.07.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。